Cayman SD 169

SD 169 is a selective ATP competitive inhibitor of the MAP kinases p38α (IC₅₀ = 3.2 nM) and p38β (IC₅₀ = 122 nM). It has no inhibitory effect against a panel of other kinases, including p38γ MAP kinase, ERK2, JNK-1, and MAPKAPK-2, when tested in vitro at 50 μM. SD 169 is orally active, significantly reducing p38 MAP kinase expression in T cells of nonobese diabetic mice when delivered in chow at 600 mg/kg. In this model, SD 169 also reduced the incidence of diabetes, lowered blood glucose, and improved glucose homeostasis. SD 169 also enhances axonal regeneration after sciatic nerve crush injury in rats, when given by gavage (30 mg/kg) before and after nerve damage.

WARNING This product is not for human or veterinary use.